ATS Medical Receives Approval

ATS Medical, Inc. (ATSI) yesterday received the CE Mark approval for marketing the ATS CryoMaze 10-S Surgical Cryoablation Probe used for the treatment of cardiac arrhythmias in the European Union.
 
The new product complements the current ATS CryoMaze Probes by adding a linear cryoablation probe that provides more controlled stiffness. This enables surgeons to have more probe leverage so that they can achieve contact with the targeted tissue that is difficult to reach.
 
The ATS CryoMaze 10-S Surgical Cryoablation Probe achieves the coldest probe temperatures needed for cardiac arrhythmia surgery. The argon-based cryoablation system can reach a temperature of -1600 Celsius versus nitrous-oxide systems that can achieve temperatures of -650 Celsius only. The colder probe temperatures provide faster and deeper lesions compared to the traditional linear lesions.
 
The ATS CryoMaze 10-S Surgical Cryoablation Probe can be easily shaped by hand without the need of any tool. The probe can be re-shaped repeatedly to meet different requirements.
 
All the new features of the product make it a necessity in cardiac arrhythmias surgeries. This will boost demand for the product, which will increase ATS Medical’s top-line.
 
Minneapolis, MN-based ATS Medical develops, manufactures and markets medical devices needed for cardiovascular surgery. The company’s products have been used in more than 140,000 heart implants across 61 countries. ATS Medical‘s core product, ATS Open Pivot -- a mechanical bileaflet heart valve -- is used to treat heart valve failure. The company also operates in the tissue valve market.
 
ATS Medical’s main competitor is St. Jude Medical Inc. (STJ - Analyst Report). Other competitors include Medtronic Inc. (MDT - Analyst Report), Carbomedics and Edwards Lifesciences (EW - Analyst Report).

Read the full analyst report on ATSI

Read the full analyst report on STJ

Read the full analyst report on MDT

Read the full analyst report on EW